 Fab fragment of belimumab. PDB: 5Y9K. | |
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | B-cell activating factor (BAFF, BLyS) |
| Clinical data | |
| Trade names | Benlysta |
| Other names | LymphoStat-B |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a611027 |
| License data | |
| Pregnancy category |
|
| Routes of administration | Intravenous, subcutaneous |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C6358H9904N1728O2010S44 |
| Molar mass | 144121.90 g·mol−1 |
  (what is this?) (verify) | |
Belimumab, sold under the brand name Benlysta, is a human monoclonal antibody that inhibits B-cell activating factor (BAFF),[6] also known as B-lymphocyte stimulator (BLyS).[7] It is approved in the United States[8] and Canada,[9] and the European Union[5] to treat systemic lupus erythematosus and lupus nephritis.[10]
The most common side effects include bacterial infections, such as bronchitis (infection in the lungs) and infection of the urinary tract (structures that produce or carry urine), diarrhea and nausea (feeling sick).[5]
- ^ "Belimumab (Benlysta) Use During Pregnancy". Drugs.com. 5 February 2020. Archived from the original on 4 December 2020. Retrieved 29 July 2020.
- ^ "BENLYSTA (GlaxoSmithKline Australia Pty Ltd)". Therapeutic Goods Administration (TGA). 11 November 2022. Retrieved 15 April 2023.
- ^ "Benlysta Product information". Health Canada. 22 October 2009. Retrieved 17 March 2023.
- ^ "Benlysta- belimumab injection, powder, lyophilized, for solution Benlysta- belimumab solution". DailyMed. 17 January 2020. Archived from the original on 25 September 2020. Retrieved 29 July 2020.
- ^ a b c "Benlysta EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 25 October 2020. Retrieved 29 July 2020.
- ^ Bossen C, Schneider P (October 2006). "BAFF, APRIL and their receptors: structure, function and signaling" (PDF). Seminars in Immunology. 18 (5): 263–275. doi:10.1016/j.smim.2006.04.006. PMID 16914324.
- ^ Kaveri SV, Mouthon L, Bayry J (September 2010). "Basophils and nephritis in lupus". The New England Journal of Medicine. 363 (11): 1080–1082. doi:10.1056/NEJMcibr1006936. PMID 20825323.
- ^ Cite error: The named reference
Mannowas invoked but never defined (see the help page). - ^ DrugBank DB08879
- ^ "Benlysta now approved in Canada in addition to standard therapy for treatment of active lupus nephritis in adult patients" (Press release). GlaxoSmithKline. 30 July 2021. Retrieved 17 March 2023 – via Newswire.